Zoledronic acid with either standard or reduced dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: A phase IV randomized study.

Conference of the Spanish-Portuguese-and -Latin-American-Association -- OCT 09, 2006 -- Leipzig, GERMANYWOS: 000242719100381Spainsh Portuguese & Latin- Amer Asso

Zoledronic acid concurrent with either high-or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: A phase IV randomized clinical study

PubMed ID: 19484483Introduction In this prospective study, the efficacy and safety of radiotherapy combined with zoledronic acid was evaluated. Materials and methods Breast cancer patients with painful bone metastases were randomized to either high- or reduced-dose radiotherapy. All patients received zoledronic acid (4 mg) every 28 days from the beginning of radiotherapy. Analgesic and pain scores in addition to visual analog score (VAS) for treatment satisfaction and whole-body bone scintigraphy were evaluated. Results and conclusion No significant differences could be found in analgesic or pain scores and bone scintigraphy results between the groups. Our results suggest that reduced-dose radiotherapy produces similar response rates and response durations when used concomitantly with zoledronic acid. © 2009 Springer-Verlag

The effect of TAB duration and pelvic RT in prostate cancers with gleason score 8-10: TROG study

WOS: 00046778630134